Assembly Biosciences (ASMB) PT Lowered to $15 at Truist Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ASMB Hot Sheet
Price: $19.92 --0%
Rating Summary:
8 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 21 | New: 12
Rating Summary:
8 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 21 | New: 12
Join SI Premium – FREE
Truist Securities analyst Nicole Germino lowered the price target on Assembly Biosciences (NASDAQ: ASMB) to $15.00 (from $45.00) while maintaining a Buy rating.
You May Also Be Interested In
- Amgen (AMGN) PT Raised to $465 at Cantor Fitzgerald
- Westpac Banking Corp. (WBC:AU) (WBK) PT Lowered to AUD41.50 at UBS
- Shopify (SHOP) PT Raised to $165 at Bernstein SocGen Group
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
